Drug Profile


Alternative Names: Recombinant anti-tumour and anti-virus protein - Genova Biotech

Latest Information Update: 27 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Genova Biotech Company
  • Developer Genova Biotech Company; The Affiliated Hospital of the Chinese Academy of Military Medical Science
  • Class Antineoplastics; Antivirals; Proteins
  • Mechanism of Action Interferon stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Colorectal cancer
  • Phase II Hepatitis B; Neuroendocrine tumours; Pancreatic cancer

Most Recent Events

  • 17 Oct 2016 Genova suspends a phase-II clinical trial in Pancreatic cancer (Late-stage disease, Second-line therapy or greater) in China prior to October 2016 (Parenteral) (ChiCTR-TRC10001000)
  • 08 Jun 2015 Phase-II development in hepatitis B is ongoing in China.
  • 01 May 2015 The Affiliated Hospital of the Chinese Academy of Military Medical Sciences plans a phase II trial for Neuroendocrine-tumours in China (NCT02455596)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top